A big shareholder is picking a proxy fight, possibly leading to a sale of a little-known drug company that last year booked more than $700 million in revenue from pain treatments.
Learn about the reasons companies report earnings at different times and how aligning their fiscal year can minimize negative seasonal impacts.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results